key: cord-0866120-s2jn12ji authors: Hashemi, Nikroo; Viveiros, Kathleen; Redd, Walker D.; Zhou, Joyce C.; McCarty, Thomas R.; Bazarbashi, Ahmad N.; Hathorn, Kelly E.; Wong, Danny; Njie, Cheikh; Shen, Lin; Chan, Walter W. title: Impact of chronic liver disease on outcomes of hospitalized patients with COVID‐19: A multicentre United States experience date: 2020-07-05 journal: Liver Int DOI: 10.1111/liv.14583 sha: 99de49c3953416aa2a6780d3f2fae0c810d41f21 doc_id: 866120 cord_uid: s2jn12ji Liver injury has been described with COVID‐19, and early reports suggested 2%‐11% of patients had chronic liver disease (CLD). In this multicentre retrospective study, we evaluated hospitalized adults with laboratory‐confirmed COVID‐19 and the impact of CLD on relevant clinical outcomes. Of 363 patients included, 19% had CLD, including 15.2% with NAFLD. Patients with CLD had longer length of stay. After controlling for age, gender, obesity, cardiac diseases, hypertension, hyperlipidaemia, diabetes and pulmonary disorders, CLD and NAFLD were independently associated with ICU admission ([aOR 1.77, 95% CI 1.03‐3.04] and [aOR 2.30, 95% CI 1.27‐4.17]) and mechanical ventilation ([aOR 2.08, 95% CI 1.20‐3.60] and [aOR 2.15, 95% CI 1.18‐3.91]). Presence of cirrhosis was an independent predictor of mortality (aOR 12.5, 95% CI 2.16‐72.5). Overall, nearly one‐fifth of hospitalized COVID‐19 patients had CLD, which was associated with more critical illness. Future studies are needed to identify interventions to improve clinical outcomes. The primary outcomes were measurements of disease severity among hospitalized COVID-19 patients with and without CLD, including the mean hospital length of stay, prevalence of ICU admission, rate of need for mechanical ventilation and all-cause in-hospital mortality. Secondary outcomes included patient characteristics (age, gender, BMI and race), prevalence of medical comorbidities (hypertension, diabetes, cardiac conditions and pulmonary disease), and laboratory results on admission (including alanine aminotransferases [ALT], aspartate aminotransferase [AST], total and direct bilirubin and alkaline phosphatase) among patients with CLD versus those without. Further analyses on clinical outcomes were also performed by stratifying patients with CLD into those with and without cirrhosis, and into NAFLD and non-NAFLD. Continuous variables were reported as means and standard deviations and categorical variables were expressed using numbers and frequencies. Student's t test and Fisher's Exact test were performed for univariate analyses for continuous and categorical variables respectively. Multivariable analyses were performed using logistic regression. All statistical analyses were performed using Statistical Analysis Software version 9.4 (SAS Institute Inc, Cary, NC, USA). The study protocol was approved by the Partners Healthcare Institutional Review Board (2020P00000983). A total of 363 patients hospitalized with confirmed COVID-19 were included, with a mean age of 63.4 years (SD ± 16.5) and 201 (55.4%) men. The mean body mass index (BMI) was 30.3 kg/m 2 (SD ± 6.6). Conditions associated with metabolic syndrome were prevalent, including 117 (32.3%) patients with diabetes, 169 (46.6%) patients with dyslipidaemia and 212 (58.4%) patients with hypertension. Overall, 69 (19%) patients were found to have underlying CLD: 55 (15.2%) patients had NAFLD, 6 (1.7%) had compensated cirrhosis (including one with NAFLD, one with alcohol-related liver disease, three with HCV, one with HBV; two patients also had hepatocellular carcinoma [HCC] ) and three (0.8%) patients had decompensated cirrhosis (two alcohol-related liver disease and one with previously treated HCV) ( Table 1 ). The cohort did not include any liver transplant recipients. On secondary analyses, we stratified CLD patients into those with NAFLD versus other aetiologies of CLD. The BMI was significantly higher among patients with NAFLD compared to those with non-NAFLD CLD (32.9 ± 6.9 vs 28.2 ± 4.9, P = .024 In this multicentre study of two tertiary and seven community hospitals in the Northeastern United States, we found that 19% of adult patients hospitalized with COVID-19 had pre-existing CLD. This is higher than published reports thus far from China and the USA. In the largest study to date from China, only the prevalence of HBV (2.1%) was reported. 12 The causes of 'liver disease' in another study, where CLD was present among 5% of patients, included NAFLD, HBV or alcohol-related. 9 In the first recently published large case series of hospitalized patients in the USA, only a few patients had underlying liver disease (cirrhosis 0.4%, HBV 0.1%, HCV < 0.1%). Other CLD including NAFLD was not reported, despite the high prevalence of metabolic comorbidities in the cohort. 15 Patients with CLD had an increased prevalence of abnormal AST and ALT levels, as well as higher mean values of AST, ALT and alkaline phosphatase on admission. However, interestingly, peak AST and ALT values during hospitalization did not differ between patients with and without CLD, possibly due to a variety of factors. The first may be due to drug hepatotoxicity, as many patients received antiviral and anti-inflammatory medications against COVID-19 during hospitalization. Second, immune-mediated inflammation, cytokine release, ischemia and congestion related to positive pressure ventilation may also contribute to liver injury among critically ill patients. Additionally, underlying liver injury or inflammation may also result in a lower hepatic reserve and lower threshold for significant injury induced by direct viral effect, immune-mediated inflammation or medications. Patients with CLD had increased length of stay, higher rates of ICU stay and need for mechanical ventilation compared to those without CLD, even after controlling for comorbidities. Interestingly, this association was observed in patients with NAFLD but not among those with non-NAFLD CLD, although this may be potentially influenced by small sample size of the non-NAFLD CLD group. This difference might also, in part, be secondary to the association between NAFLD and obesity, as the mean BMI of NAFLD patients was significantly higher compared to that of non-NAFLD CLD patients. Prior studies have identified increased morbidity in patients with obesity in the ICU. 16 There was also an observed higher rate of mechanical ventilation among severely obese hospitalized patients with COVID-19 in a recent US study. 3 The pro-inflammatory state associated with obesity may contribute to the increased disease severity associated with COVID-19, with potentially higher risk for complications such as acute respiratory distress syndrome (ARDS), as has previously been observed among non-COVID-19 populations. 17, 18 However, the increased rates of clinical severity among NAFLD patients were observed even after controlling for the presence of obesity, suggesting that the effect of NAFLD on disease severity may be due to more than increased BMI alone. A prior study found liver fat to be associated with higher serum markers of inflammation and oxidative stress. 19 NAFLD has also been linked to reduction in lung function measured on pulmonary function test. 20 These In summary, in our cohort of hospitalized US adults with COVID-19, approximately one in five patients had underlying CLD, of whom 13% had confirmed cirrhosis. While patients with NAFLD were more likely to be admitted to the ICU and require mechanical ventilation, only those with cirrhosis, which were mostly secondary to non-NA-FLD CLD in our cohort, had an increased risk of mortality. Further research is needed to better understand the effect of underlying CLD, specifically NAFLD, on the severity of COVID-19 and identify interventions to improve patient outcomes. Nikroo Hashemi has no conflicts to disclose. Kathleen Viveiros has no conflicts to disclose. Walker D. Redd has no conflicts to disclose. Joyce C. Zhou has no conflicts to disclose. Thomas R. McCarty has no conflicts to disclose. Ahmad Najdat Bazarbashi has no conflicts to disclose. Kelly E. Hathorn has no conflicts to disclose. Danny Wong has no conflicts to disclose. Cheikh Njie has no conflicts to disclose. Lin Shen has no conflicts to disclose. Walter W. Chan has no conflicts to disclose. Administrative support and overall study supervision -WWC. Walter W. Chan https://orcid.org/0000-0002-1709-8230 COVID-19) pandemic. Latest updates. World Health Organization Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Association of obesity with disease severity among patients with COVID-19 Effect of gastrointestinal symptoms on patients infected with coronavirus disease 2019 Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms Burden of liver diseases in the world Liver injury in COVID-19: management and challenges Clinical features of COVID-19-Related Liver Damage COVID-19: Abnormal liver function tests Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected Pneumonia in Wuhan Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study Clinical characteristics of coronavirus disease 2019 in China Coronavirus disease 2019 and prevalence of chronic liver disease: a meta-analysis Clinical features of patients infected with 2019 novel coronavirus in Wuhan Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the Obesity in the critically ill: a narrative review Body mass index is associated with the development of acute respiratory distress syndrome Obstructive sleep apnea, obesity, and the development of acute respiratory distress syndrome Liver fat is associated with markers of inflammation and oxidative stress in analysis of data from the framingham heart study Association between non-alcoholic fatty liver disease and decreased lung function in adults: a systematic review and meta-analysis Clinical characteristics and outcomes of COVID-19 among patients with pre-existing liver disease in United States: a multi-center research network study Additional supporting information may be found online in the Supporting Information section.